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Objective: Initiation and intensification of insulin therapy commonly causes weight gain, a barrier to therapy. A contrasting
body of evidence indicates that insulin functions as an adiposity negative feedback signal and reduces food intake, weight gain
and adiposity via action in the central nervous system. Basal insulin analogs, detemir (Det) and glargine (Glar), have been
associated with less hypoglycemia compared with neutral protamine hagedorn insulin, and Det with less weight gain, especially
in patients with higher body mass index (BMI). We sought to determine whether insulin therapy per se causes body weight and
fat mass gain when delivered via a clinically relevant subcutaneous (SC) route in the absence of hypoglycemia and glycosuria in
non-diabetic lean and diet-induced obese rats.
Materials and methods: Rats were exposed to either a low-fat diet (LFD; 13.5% fat) or high-fat diet (HFD; 60% fat), and
received Det (0.5Ukg
 1), Glar (0.2Ukg
 1) or vehicle (Veh) SC once daily for 4 weeks. These dosages of insulin were equipotent
in rats with respect to blood–glucose concentration and did not induce hypoglycemia.
Results: As predicted by current models of energy homeostasis, neither insulin Det nor Glar therapy affected food intake and
weight gain in LFD rats. Det treatment significantly attenuated food intake, body weight gain and fat mass gain relative to the
Glar and Veh in high-fat fed animals, mirroring observations in humans.
Conclusions: That neither insulin group gained excess weight, suggests weight gain with SC basal insulin therapy may not be
inevitable. Our data further suggest that Det possesses a unique property to attenuate the development of obesity associated
with a HFD.
Nutrition and Diabetes (2011) 1, e10; doi:10.1038/nutd.2011.6; published online 4 July 2011
Keywords: insulin; weight gain; energy homeostasis; brain
Introduction
Together with obesity, diabetes is epidemic in the US and
worldwide.
1 Weight gain is both a risk factor for diabetes and
a consequence of initiation and intensification of insulin
therapy, as illustrated in landmark diabetes control trials.
2–4
Weight gain associated with increased adiposity can worsen
insulin resistance leading to higher insulin requirements,
and thus perpetuates a vicious cycle. Weight gain addition-
ally generates further risk for macrovascular outcomes such
as cardiovascular disease
5,6 and generates negative ‘biofeed-
back’ to the patient and physician struggling to achieve
glycemic control.
Mechanisms involved in weight gain associated with
insulin therapy are incompletely understood. Hypoglycemia
is a potent stimulus to feed,
7 improving glycemic control
reverses the negative energy balance associated with glyco-
suria, and insulin potently stimulates lipogenesis. Indeed
insulin is an anabolic hormone in peripheral tissues.
8
Although weight gain on insulin initiation or intensification
is common, there are reports in randomized, controlled
human clinical trials of attenuation of this effect associated
with the use of a basal insulin analog, detemir (Det),
compared with other insulins used in subjects with type 1
and type 2 diabetes
9 (as reviewed in Hermansen and
Davies
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who are predicted to be more insulin resistant. Det has also
been shown to have enhanced effects on central nervous
system (CNS) function in both experimental animals
11 and
human subjects.
12,13 So-called basal insulins are long-acting
insulin formulations that maintain euglycemia between
meals and overnight (that is, fasting) primarily by limiting
hepatic glucose production.
14 Frequently, type 2 diabetes
insulin therapy is initiated with basal insulin.
In contrast to ample evidence associating insulin therapy
with increased adiposity and weight gain, a distinct body of
evidence indicates that insulin functions as an adiposity
negative feedback signal to the CNS.
15 Insulin (and leptin) is
secreted in proportion to body fat stores,
16 and regulates the
function of key homeostatic neurons found in the medio-
basal hypothalamus
17 and elsewhere,
18 which in turn,
control feeding, energy expenditure and other aspects of
neuroendocrine physiology (reviewed in Niswender et al.
17
and Plum et al.
19). Although a potent anabolic stimulus in
peripheral tissues, insulin action in the CNS is catabolic in
the sense that it reduces food intake, weight gain and
adiposity. Thus, a paradox emerges when one considers
that insulin therapy is associated with weight gain,
whereas in experimental situations insulin functions to limit
weight gain.
A number of elegant basic science approaches have
clarified the role of insulin in energy homeostasis. Insulin
administration directly into the brain reduces food
intake
20–22 and targeted mutation of insulin signaling
components in neurons leads to weight gain.
23,24 Here, we
sought to engage a more clinically relevant approach to the
question of whether it is insulin therapy per se (rather than
hypoglycemia, reversal of negative energy balance and so on)
that causes weight gain in a well-controlled preclinical
model. Herein we tested the chronic effects of modern basal
insulin analogs, Det and glargine (Glar). As basal insulins,
Det and Glar, are used clinically to control between meal and
overnight hyperglycemia,
14 and were chosen here because
they could be delivered by the clinically relevant subcuta-
neous (SC) route without causing hypoglycemia due to their
pharmacodynamic profiles.
25 We have controlled for con-
founding variables such as glycosuria, negative energy
balance and hypoglycemia by studying non-diabetic, but
high-fat (HF) fed diet-induced obese rats compared with low-
fat (LF) fed rats. Thus, we used long-acting basal insulin
analogs to replace some percentage of endogenous basal
insulin (that rate needed to maintain euglycemia in the
fasting state) allowing us to avoid hypoglycemia and thereby
to test the effects of these insulins per se on feeding and
weight gain. We hypothesized that the anabolic effects of
insulin in peripheral tissues will be balanced by the catabolic
effects in the CNS when confounders are controlled, and
that Det might attenuate weight gain, especially on HF diet.
Thus, in the absence of negative energy balance and
hypoglycemia, we sought to ask whether chronic SC basal
insulin therapy still leads to weight gain and increased
adiposity and whether we can model the observed effects of
Det to limit weight gain in the setting of obesity.
Materials and methods
Animals and dietary treatment
After an acclimation period, individually housed male
Sprague–Dawley rats (250–274g, Harlan, Indianapolis, IN,
USA) were fed a LF diet (LFD; 5001, Lab diet, Richmond, IN,
USA; 3.02kcalg
 1, 58% carbohydrate, 28.5% protein, 13.5%
fat; n¼15) or a HF diet (HFD; D12492, Research Diets, New
Brunswick, NJ, USA; 5.24kcalg
 1, 20% carbohydrate, 20%
protein, 60% fat; n¼21) to induce obesity.
26 Food intake and
body weight were measured daily and adiposity measured
three times weekly using an EchoMRI-700 nuclear magnetic
resonance (NMR, Echo Medical Systems, Houston TX, USA).
All experimental protocols were approved by the Vanderbilt
Institutional Animal Care and Use Committee.
Insulin preparation
Det (Levemir; 100Uml
 1; Novo Nordisk, Bagsvaerd,
Denmark) was freshly prepared daily in Det dilution media
(140mM NaCl, 70p.p.m. Tween-20, 5mM NaH2PO4, pH 7.4)
and administered SC at 0.5Ukg
 1 body weight in 250ml.
Similarly, Glar (Lantus; 100Uml
 1; Sanofi-Aventis, Paris,
France) was freshly prepared daily in Glar dilution media
(1ml contains 30mg zinc, 20mg of 85% glycerol, 20mg
Tween-20, pH 4.0) dosed SC at 0.2Ukg
 1 body weight in
250ml. Modestly, insulin resistant humans might use
between 0.2–0.8U basal insulin per kg body weight per
24h (KD Niswender, personal experience). All the insulin
was purchased from the Vanderbilt Outpatient Pharmacy
(Nashville, TN, USA). Vehicle (Veh) treated rats received
either Det dilution media or Glar dilution media in the same
volume as the insulin treated groups (250ml). Outcomes of
both Veh groups were not different and were combined for
presentation.
Insulin dosing and equipotency
Different insulin formulations have varying potencies
among species,
27 and insulin is used clinically for glycemic
control. Therefore, we sought to conduct our studies at
dosages of Det and Glar that were equipotent in rats. After a
baseline blood–glucose measurement, SC insulin injections
were administered and blood samples were collected by tail
prick at 30-min intervals up to 360min. Blood–glucose
concentration was measured using a glucometer (Cardinal
Health, Dublin, OH, USA). Extensive insulin tolerance
testing (ITT, data not shown) revealed that a dose of
0.5Ukg
 1 body weight of Det was equal to 0.2Ukg
 1 body
weight of Glar (2.5:1 unit ratio, Det:Glar) for effects on
glycemia. This relative potency in rats was the same as
observed by other investigators using hyperinsulinemic–
euglycemic clamp techniques in rats.
27
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Animals were randomized to receive Det (n¼11), Glar
(n¼13) or Veh (n¼12). Insulin or Veh was administered in
the subscapular region daily at the onset of the dark cycle for
the initial 4-week acclimation period of LF-feeding. Subse-
quent to acclimation, at day 0, a subset of animals from each
treatment group were randomly assigned to HFD (n¼21;
6 Det, 8 Glar and 7 Veh) or remained on LFD (n¼15; 5 Det,
5 Glar, 5 Veh), and all animals continued to receive the same
insulin or Veh treatments for an additional 4 weeks.
Indirect calorimetry
Indirect calorimetry was performed on LF- (n¼7–8 per
group) and HF-fed (n¼6–8 per group) rats using an open-
circuit indirect calorimeter (Oxymax; Columbus Instru-
ments, Columbus, OH, USA). Average respiratory quotient
(RQ) was calculated as the molar ratio of VCO2:VO2 in a 24-h
period. Energy expenditure (kcal per day) was calculated
as heat (kcal/h
 1)¼(3.815þ1.232 RQ) VO2.
28 Energy
balance (kcal per day) was calculated from the energy
expenditure (kcal per day) minus the energy intake (kcal
per day). Rats received their respective insulin or Veh
treatments before onset of the dark cycle period during
calorimetry.
Study termination
Four hours after receiving SC injection of their respective
treatments both LFD and HFD groups were euthanized.
Plasma was collected, as were epididymal white adipose
tissue (snap frozen on dry ice), and stored at  801C until
assayed.
RNA quantification using real-time PCR
Epididymal white adipose tissue samples were homogenized
and RNA was isolated using TRIzol reagent (Invitrogen,
Carlsbad, CA, USA). From these RNA samples, complemen-
tary DNA (cDNA) was synthesized using High Capacity
cDNA Reverse Transcription Kit (Applied Biosystems, Foster
City, CA, USA). Real-time PCR was conducted using standard
curves in each assay (six-point serial dilution of cDNA
synthesized from XpressRef rat universal total RNA; Super-
Array Bioscience, Frederick, MD, USA), IQ SYBR Green
Supermix and performed in triplicate using the I-Cycler
thermal cycler (Bio-Rad, Hercules, CA, USA) with 1 cycle of
951C for 3min followed by 40 cycles of 951C for 30s,
optimal annealing temperature for 30s and 721C for 30s.
Only experiments with 490% efficiency of amplification
were used. Quantification results for each RNA of interest
were normalized to the housekeeping gene, ribosomal
protein L13a (RPL13a) and for comparative analysis, RNA
ratios of HF and LF groups were normalized to the Veh-
treated LF control group. The sequences and optimal
annealing temperature of each primer pair used for RNA
quantification are available on request.
Lipid assays
Lipids were assayed from plasma with enzymatic colori-
metric assays using the following reagent kits; triglycerides
and total cholesterol (Raichem, San Diego, CA, USA), non-
esterified fatty acids (Wako Diagnostics, Richmond, VA, USA)
and glycerol (Sigma-Aldrich, St Louis, MO, USA). The
reported intra-assay coefficient of variation (CV) for all lipid
assays is within 1%.
Plasma hormones and metabolites
Plasma levels of leptin (Rat Leptin RIA kit, Millipore,
Billerica, MA, USA) and corticosterone (ImmuChem Double
Antibody RIA kit, MP Biomedicals, Solon, OH, USA) were
quantified using radioimmunoassay by the Vanderbilt
Diabetes Center Hormone Assay and Analytical Services
Core (Nashville, TN, USA). The reported CVs for leptin and
corticosterone were 2–5% and 4%, respectively. Adiponectin
was assessed by ELISA (RT Biosource, Invitrogen, Camarillo,
CA, USA) with a reported CV of 2–4%.
Statistical analysis
Data are presented as the mean±s.e.m. Equipotency and
lack of hypoglycemia in the ITT testing of Det vs Glar
treatment were analyzed using Student’s two-tailed,
unpaired t-test. The main effect of diet and insulin therapy
on food intake, body weight and adipose mass over the
4-week period were compared by two-way repeated measures
analysis of variance (ANOVA) with Bonferroni’s post-test
analysis. The main effect of diet and insulin therapy on body
weight gain and fat mass gain, energy homeostasis and
metabolic parameters were compared using two-way ANOVA
with Bonferroni’s post-test analysis. All analysis was per-
formed using Prism, version 5.02, 2008 (GraphPad Software,
San Diego, CA, USA). Differences of Po0.05 were considered
statistically significant.
Results
Insulin potency and dosing
We sought to study the effects of insulin Det and Glar on
food intake and weight gain at doses that were equipotent
with respect to blood–glucose concentration, since insulin is
used clinically for glycemic management. In preliminary
ITTs (data not shown), we determined that a dose of
0.5Ukg
 1 body weight of Det was equipotent with that of
0.2Ukg
 1 body weight of Glar with respect to changes in
blood glucose, which is consistent with observations of
others in rats.
27 Because hypoglycemia is a potent hyper-
phagic stimulus,
29 additional ITTs were conducted during
this study in both HF- and LF-fed rats receiving Det
(0.5Ukg
 1) and Glar (0.2Ukg
 1) to assess insulin-induced
hypoglycemia (Figure 1). These doses of insulin did not
induce hypoglycemia with blood glucose at 90min in
LF-fed rats (Figure 1a; Glar 5.1±0.1mmoll
 1 vs Det
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 1, P¼NS) and in HF-fed rats (Figure 1b; Glar
4.7±0.1mmoll
 1 vs Det 4.7±0.1mmoll
 1, P¼NS). ITTs
were also conducted in animals included in this study
covering 24h of insulin exposure to assess for a delayed
onset of insulin-induced hypoglycemia and to assure that
the doses of insulin remained equipotent. Twenty hours after
insulin injection blood–glucose concentrations were not
significantly different among the HFD (5.6±0.1mmoll
 1 for
Glar and 5.3±0.1mmoll
 1 for Det, P¼NS) and LFD
(5.3±0.1mmoll
 1 for Glar vs 5.3±0.1mmoll
 1 for Det,
P¼NS) groups. In a separate study, we observed that higher
doses of insulin did significantly lower glycemia and induce
compensatory increases in feeding (data not shown).
Food intake
Here, we sought to determine the effects of relatively low-
dose basal insulin therapy on food intake in both LF- and HF-
fed animals. We observed in the LFD groups that neither
insulin Det or Glar increased nor decreased cumulative food
intake (Figures 2a and c) compared with Veh. Conversely,
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Figure 1 Glycemic effects of Det and Glar in rats. (a, b) Blood glucose was
determined at indicated time points after SC insulin administration of Det
0.5Ukg
 1 (triangle) or Glar 0.2Ukg
 1 (diamond) in LF-fed rats (a; n¼11–13
per group) or HF-fed rats (b; n¼6–8 per group). Data are presented as the
mean±s.e.m. and were analyzed by Student’s two-tailed, unpaired t-test;
P¼NS, Glar vs Det.
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Figure 2 Effects of Det and Glar on food intake in LFD and HFD rats. Food
intake was measured daily for each treatment group, Veh (circle), Det (triangle)
and Glar (diamond); and presented as cumulative food intake in rats fed either
LFD (a; n¼5 per group) or HFD (b; n¼6–8 per group). Total cumulative food
intake for each treatment and diet group is shown (c). Data are presented as the
mean±s.e.m. and were analyzed by two-way repeated measures ANOVA.
Bonferroni’s post-test shows that Det reduced cumulative food intake in HF-fed
rats relative to Glar from 10 to 27 days and relative to Veh from 24 to 27 days. For
all panels: *Po0.05 for Veh vs Det;
#Po0.05,
aPo0.01 and
bPo0.001 for Glar vs
Det comparisons as analyzed by Bonferroni’s post-test.
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Nutrition and DiabetesDet reduced cumulative food intake in HF-fed rats by 7%
relative to Veh and by 10% relative to Glar (whereas Glar had
no effect compared with Veh) resulting in a lower 4-week
cumulative food intake (Figures 2b and c; Veh 2296±55kcal,
Glar 2379±72kcal, Det 2130±47kcal; Veh vs Det Po0.05,
Glar vs Det Po0.001, Veh vs Glar P¼NS). Clearly, the effect
of Det to reduce food intake was dependent on HFD intake
(F(5,30)¼44.82; Po0.0001).
Body weight and adipose mass
Because we observed significant attenuation of cumulative
food intake in HF-fed rats receiving Det, the effect of basal
insulin therapy on body weight and fat mass gain was of
primary interest. Consistent with the food intake data in the
LFD group neither Det nor Glar therapy had any effect on
daily body weight and fat mass (Figures 3a and d) or body
weight or fat mass gain (Figures 3c and f). In contrast, in HFD
rats, Det trended to attenuate daily body weight (Figure 3b),
but this did not reach statistical significance for any
individual day over the 4-week period. Det did, however,
reduce body weight gain relative to both Veh and Glar,
whereas Glar had no effect compared with Veh (Figure 3c;
Veh 72.0±4.8g, Glar 72.5±4.0, Det 59.2±3.5; Veh vs Det
Po0.05, Glar vs Det Po0.05, Veh vs Glar P¼NS). The effect
of Det to reduce body weight was clearly dependent on HFD
intake (F(5,30)¼6.10; Po0.001).
Fat mass was significantly reduced by Det compared with
both Veh and Glar on HFD (Figure 3e, Po0.05 from day 10
onward). Fat mass gain was significantly lower in the Det
group relative to Veh and Glar, Glar had no effect compared
with Veh (Figure 3f; Veh 36.6±2.9g, Glar 39.2±3.3g, Det
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Figure 3 Insulin Det attenuates weight and adipose gain in HFD, but not LFD rats. Body weight was measured daily in rats fed either LFD (a; n¼5 per group) or
HFD (b; n¼6–8 per group) for each treatment group; Veh (circle), Det (triangle) and Glar (diamond). Body weight gain was determined for the 4-week study period
for all groups (c). Fat mass was measured three times weekly by NMR in rats fed either LFD (d; n¼5 per group) or HFD (e; n¼6–8 per group) for each treatment
group; Veh (circle), Det (triangle) and Glar (diamond). Fat mass gain was determined for the 4-week study period for all groups (f). Data are presented as the
mean±s.e.m. and were analyzed by either two-way repeated measures ANOVA (for body weight and fat mass) or two-way ANOVA (for body weight and fat mass
gain). Bonferroni’s post-test shows that daily fat mass (e) was reduced by Det relative to Veh from 13 to 26 days and relative to Glar from 10 to 26 days. For all
panels: *Po0.05, **Po0.01, and ***Po0.001 for Veh vs Det;
#Po0.05,
aPo0.01 and
bPo0.001 for Glar vs Det comparisons as analyzed by Bonferroni’s post-test.
Insulin detemir attenuates diet-induced obesity in rats
JM Rojas et al
5
Nutrition and Diabetes25.6±2.9g; Veh vs Det Po0.05, Glar vs Det Po0.01, Veh vs
Glar P¼NS). The effect of Det to reduce fat mass was clearly
dependent on HFD intake (F(5,30)¼8.15, Po0.0001).
Energy balance
We assessed energy expenditure in LF- and HF-fed rats by
indirect calorimetry using an open-circuit indirect calori-
meter. No significant differences in energy expenditure were
noted (Table 1). HF-fed rats treated with Det had reduced
calculated positive energy balance relative to Veh (Veh vs
Det, Po0.05) and to Glar (Glar vs Det, Po0.01) and this was
due entirely to a significant reduction in energy intake
(Table 1; Veh vs Det, Po0.05 and Glar vs Det, Po0.001). Also
as expected, lower RQ values were observed among the HFD
groups in comparison to LFD groups indicating that the HF-
fed animals were oxidizing fats to a greater extent as their
primary fuel substrate (F(1,38)¼678.40; Po0.0001).
Plasma lipids, hormones and metabolites
We assessed several plasma lipid, hormonal and metabolite
markers to determine whether insulin therapy in HF-fed rats
alters the metabolic milieu. We observed that only Glar
treatment in the LFD and not the HFD rats had significantly
lower plasma triglycerides (TG) relative to Veh (Table 2; Veh
vs Glar, Po0.05). Overall, we observed no effects of insulin
Det or Glar therapy on total cholesterol (Chol), free fatty
acids (FFA) or glycerol (Table 2). We measured adiponectin
(ADN) levels as an index of adiposity and insulin sensitiv-
ity,
30 and no differences were observed (Table 2). Corticos-
terone (Cort) levels were quantified as an index of potential
counter-regulatory response to unrecognized insulin-in-
duced hypoglycemia,
31 and no differences were observed
(Table 2). As might be predicted with lower fat mass in the
HFD group, Det-treated animals had lower plasma leptin
levels compared with Veh- and Glar-treated animals (Table 2).
However, the effect of Det to reduce leptin in HF-fed rats did
not reach statistical significance (F(2,28)¼1.65; P¼0.21).
White adipose tissue markers of insulin action
Insulin is a potent stimulator of lipogenesis,
32 thus we
assessed the insulin-sensitive transcriptional markers,
33 fatty
acid synthase (FAS) and lipoprotein lipase (LPL), by real-time
PCR on cDNA prepared from epididymal white adipose tissue
(WAT) samples to determine whether adipose-specific effects
could be identified. Glar treatment in HFD rats significantly
increased FAS RNA levels relative to Veh and Det, whereas
Det had no effect compared with Veh (Figure 4a; Veh
1.2±0.3, Glar 2.1±0.4, Det 1.1±0.1; Veh vs Glar Po0.05,
Glar vs Det Po0.05, Veh vs Det P¼NS). Clearly, the effect of
Glar to increase FAS RNA expression was dependent on HFD
intake (F(2,30)¼7.69; Po0.01). Glar-treated LFD rats had
increased LPL RNA relative to Veh and Det, whereas Det had
no effect relative to Veh (Figure 4b; Veh 1.0±0.1, Glar
2.3±0.3, Det 0.9±0.3; Veh vs Glar Po0.001, Glar vs Det
Po0.001, Veh vs Det P¼NS). The effect of Glar on LPL RNA
was dependent on LFD intake (F(2,32)¼16.00; Po0.0001). It
is well documented that HFD can induce adipose tissue
Table 1 Effects in LF (n¼7–8 per group) and HF-fed (n¼6–8 per group) rats of insulin therapy on energy balance as assessed by indirect calorimetry using an
open-circuit indirect calorimeter in a 24h period
Group Energy intake (kcal per day) Energy expenditure (kcal per day) Energy balance (kcal per day) Respiratory quotient (VCO2:VO2)
Veh LF 66.7±1.4 49.3±1.0 17.4±1.7 0.808±0.006
Det LF 67.2±1.0 49.7±1.5 17.5±1.1 0.806±0.005
Glar LF 65.8±0.9 50.9±0.7 14.9±0.8 0.813±0.004
Veh HF 81.4±1.8* 57.4±1.9 24.0±1.8* 0.718±0.003
Det HF 75.3±1.6 57.7±1.7 17.6±2.7 0.718±0.002
Glar HF 85.1±2.6
b 58.5±1.3 26.6±2.2
a 0.712±0.004
Abbreviations: Det, detemir; Glar, glargine; HF, high fat; LF, low fat; Veh, vehicle. Data are presented as the mean±s.e.m. and were analyzed by two-way ANOVA.
Analysis with Bonferroni’s post-test shows for HF-fed rats: *Po0.05 for Veh vs Det;
aPo0.01 and
bPo0.001 for Glar vs Det comparisons.
Table 2 Effects of insulin therapy on plasma lipids, hormones and metabolites after 4 weeks of either HF (n¼6–8 per group) or LF (n¼5 per group) diet
feeding of rats
Group TG (mmoll
 1) Chol (mmoll
 1) FFA (mmoll
 1) Glycerol (mmoll
 1) ADN (mgl
 1) Cort (nmoll
 1) Leptin (mgl
 1)
Veh LF 0.83±0.22 2.73±0.19 0.37±0.04 1170±112 17.4±2.1 403±47 1.5±0.3
Det LF 0.64±0.11 2.63±0.18 0.40±0.05 1170±114 14.0±1.4 403±43 1.0±0.4
Glar LF 0.44±0.04
# 2.63±0.12 0.38±0.05 905±105 17.4±1.1 500±66 1.8±0.6
Veh HF 0.74±0.05 3.65±0.21 0.47±0.04 1353±102 18.7±1.2 429±53 5.8±1.1
Det HF 0.73±0.03 3.53±0.21 0.39±0.02 1399±138 17.3±0.7 451±79 3.4±0.3
Glar HF 0.69±0.04 3.37±0.34 0.39±0.03 1105±134 18.3±0.9 530±87 6.5±1.4
Abbreviations: ADN, adiponectin; Chol, cholesterol; Cort, corticosterone; Det, detemir; FFA, free fatty acid; Glar, glargine; HF, high fat; LF, low fat; TG, triglyceride;
Veh, vehicle. Data are presented as the mean±s.e.m. and were analyzed by two-way ANOVA. Analysis with Bonferroni’s post-test shows for LF-fed rats:
#Po0.05 for
Veh vs Glar comparison.
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resistance and cardiovascular disease.
34 On both LFD and
HFD, basal insulin therapy had no significant effect on the
expression of the proinflammatory cytokine, tumor necrosis
factor-a (data not shown).
Discussion
For clinicians, the concept that insulin functions as an
adiposity negative feedback signal to the CNS and controls
food intake and weight gain, first proposed by Porte and
Woods in the late 1970s,
35,36 is quite at odds with clinical
experience where insulinization rather uniformly leads to
weight gain. Whereas B2kg of weight gain is typically
expected for each 1% reduction in HbA1C, insulin adminis-
tered directly into the CNS of animals ranging from
baboons
20 to rodents
22 will lower food intake and body
weight. Genetic modifications that reduce insulin signaling
in mice
23,24 as well as mutations in insulin signaling
homologs in even more primitive organisms, such as flies
and nematodes,
17 lead to increased fat mass in these
organisms.
Here we describe, for the first time to our knowledge, the
robust effect of peripheral SC Det insulin administration to
reduce food intake and limit weight and adipose gain.
Explanations for weight gain on insulin therapy commonly
include reversal of the negative energy balance associated
with glycosuria, anabolic effects of insulin in peripheral
tissues, particularly the potent effect to stimulate lipogen-
esis, and the fact that hypoglycemia is a potent stimulus to
feed. Finally, it has been described that, with imperfect
pharmacodynamic profiles, humans will learn to anticipate
hypoglycemia and eat defensively.
8 By controlling for these
variables, we appear to have uncovered a unique effect of
insulin Det, but not Glar, to modulate weight gain.
In these studies, we sought to carefully examine the role of
insulin delivered ‘clinically’ (that is, given subcutaneously,
once daily) on energy homeostasis. Of course, insulin
delivered directly into the brain decreases feeding,
20–22 but
our primary objective was to specifically address whether it is
the insulin per se that causes weight gain when given via a
clinically relevant (SC) route. Here, we sought to bridge
clinical experience with our basic science understanding of
the role of insulin in energy homeostasis. We additionally
controlled for confounders that may explain weight gain by
studying non-glycosuric, non-diabetic animals without
causing hypoglycemia. Furthermore, because potential
weight effects might be amplified in a model of rapid weight
gain (diet-induced obese) and because of the clinical
observation that weight sparing effects of Det appear to be
amplified in the most obese subjects, we also studied the
effects in animals on HFD.
First, as current models of energy homeostasis predict, SC
insulin neither increased nor decreased food intake and
weight gain in LFD rats. The doses of insulin used here are
within the clinically relevant dosage range for treatment of
diabetes in humans with modest insulin resistance (B0.2–
0.8Ukg
 1 per day, KD Niswender, personal experience).
Conversely, on HFD, a surprisingly robust effect of Det, but
not Glar, to attenuate food intake, weight gain and adipose
gain was observed. First, this implies an important interac-
tion of diet with Det for effects on weight and is intriguingly
consistent with observations in humans where those
individuals with higher body mass index benefited most.
9
Of course, in terms of fat content, the typical human diet
much more closely resembles the HFD, rather than the LFD,
which consists of only 13.5% calories from fat. Indeed, this
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Figure 4 Effects of Det and Glar on RNA levels of white adipose tissue
markers of lipogenesis. RNA isolated from epididymal fat of rats of all
treatment groups (Veh, Det and Glar) after 4 weeks of diet consisting of either
LFD (n¼5 per group) or HFD (n¼6–8 per group) was assessed by real-time
PCR for changes in RNA levels of WAT lipogenic markers, fatty acid synthase
(FAS) (a) and lipoprotein lipase (LPL) (b). RNAs of interest were normalized to
RPL13a and for comparative analysis, RNA ratios were normalized to the Veh
LF control. Data are presented as the mean±s.e.m. and were analyzed by
two-way ANOVA. For all panels, analysis with Bonferroni’s post-test shows:
*Po0.05 and ***Po0.001 for Veh vs Det;
#Po0.05,
bPo0.001 for Glar vs Det
comparisons.
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Nutrition and Diabetesfood intake and weight attenuating effect is eliminated with
increasing dose of insulin (not shown), suggesting, not
surprisingly, a narrow effective ‘window.’ Because it is
clinically very difficult in humans to remain precisely within
such a window due to variability in (1) caloric and
macronutrient intake, (2) in insulin administration, and (3)
in insulin absorption it is perhaps not surprising that weight
gain is common. Weight gain is clearly one of the major
barriers to successful clinical use of insulin and our findings,
albeit in a preclinical model, suggest that with careful use,
insulin need not inevitably cause weight gain. This conclu-
sion is similar to that drawn from a longitudinal study
comparing weight gain in controlled diabetics on insulin vs
oral agents.
37 That the weight effects of Det were observed
under HF dietary conditions that provoke weight gain, and
that most experts agree contribute to human obesity and
diabetes suggests that this model may hold promise for
understanding pathophysiological and potentially therapeu-
tic mechanisms at the interface of feeding, obesity and
diabetes. Finally, that the effect is observed only on HFD
implies that the increased molar ratio of Det to Glar required
to obtain similar glycemic effects is not the sole explanation
for the observed weight effects, as the same ratio was utilized
in LF-fed rats where no effects were observed.
Several studies investigating the effect of chronic admin-
istration of insulin in normal-weight or obese non-diabetic
rat models have largely reported findings that insulin
treatment either had no effect
38 or induced hyperphagia
and weight gain.
39–45 Notably, only a study by Vander-
weele
46 showed an 11% reduction of spontaneous daily food
intake in normal-weight chow-fed rats administered 2U per
day of regular insulin via an osmotic minipump implanted
into the peritoneal cavity. Thus, our findings with insulin
Det appear to be fundamentally novel.
Although the primary objective of our study was to
determine the effects of SC basal insulin regimens on energy
homeostasis in a unique preclinical diet-induced obese
model, we also took the opportunity to explore, in a
preliminary way, insulin-sensitive markers of potential
mechanisms underlying the phenotype. Others have hy-
pothesized that relative tissue selectivity, particularly for the
CNS, could explain such weight effects.
47,48 For example, a
recent study in humans demonstrated effects of Det on brain
function and to reduce spontaneous food intake in a test
meal.
12 Conversely, others have determined that Det has
attenuated transport into the CNS,
49 suggesting the possibi-
lity that findings of reduced food intake in humans and
rodents may be indirect.
Given that insulin has potent lipogenic effects, and
that we observed significant attenuation of fat mass gain
in Det-treated HFD rats, we assessed expression of key
insulin-sensitive target genes in adipose tissue. Here, Glar
was noted to increase fatty acid synthase gene expression in
both HFD and LFD groups, and to increase lipoprotein lipase
gene expression in LFD rats, both effects that would promote
storage of fat in adipose. Det showed no effects on adipose
tissue gene expression among the groups. These findings are
consistent with potency studies in vitro where Glar was noted
to have roughly double the lipogenic potency of Det and
B80-fold increased mitogenic potency.
50 Coupling in vitro
and in vivo findings such as these raises the possibility that
future insulin analog development may enhance specific
aspects of insulin’s pleiotropic effects while minimizing
others, including those on weight. This will clearly require
an improved understanding of the molecular pharmacolo-
gical mechanisms underlying such effects.
Insulin-associated weight gain contributes to clinical
inertia, resulting in many patients with diabetes failing to
achieve adequate glycemic control, and increasing risk for
other metabolic comorbidities. We conclude here that insulin
therapy may not necessarily and inevitably lead to weight
gain and that it is not the insulin per se that is responsible
when weight gain occurs. Next, we have clearly unmasked a
unique property of Det in these studies to influence energy
balance. Obesity is thought to arise from a very small
mismatch in caloric intake vs expenditure; as little as a 1%
mismatch can lead to significant weight gain. Here, we
observed an overall 7–10% reduction in caloric intake,
consistent with recent findings in human volunteers where
Det significantly reduced food intake compared with regular
human insulin.
12 Recognizing significant differences in rat vs
human physiology, if such a magnitude of effect were indeed
achievable in humans it would have an enormous impact on
diabetes progression and obesity related comorbidities. All too
commonly, insulin therapy in humans is reserved for ‘rescue’
or ‘last-ditch’ therapy, after the failure of multiple oral
medications to control blood–glucose concentration. Several
compelling recent publications, however, demonstrated that
early insulinization had potential beneficial effects on disease
progression.
51,52 These were primarily glycemia-focused inter-
vention studies, but it is intriguing to consider what a similar,
but weight-focused approach might achieve.
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